daptomycin for injection powder for solution
pfizer canada ulc - daptomycin - powder for solution - 500mg - daptomycin 500mg - cyclic lipopeptides
daunorubicin injectable solution
generic medical partners inc - daunorubicin (daunorubicin hydrochloride) - solution - 20mg - daunorubicin (daunorubicin hydrochloride) 20mg - antineoplastic agents
daunorubicin injectable solution
generic medical partners inc - daunorubicin (daunorubicin hydrochloride) - solution - 50mg - daunorubicin (daunorubicin hydrochloride) 50mg - antineoplastic agents
daptomycin for injection powder for solution
sandoz canada incorporated - daptomycin - powder for solution - 500mg - daptomycin 500mg - cyclic lipopeptides
daunorubicin hydrochloride injection solution
hikma canada limited - daunorubicin (daunorubicin hydrochloride) - solution - 20mg - daunorubicin (daunorubicin hydrochloride) 20mg
daptomycin injection, powder, lyophilized, for solution
hospira, inc. - daptomycin (unii: nwq5n31vkk) (daptomycin - unii:nwq5n31vkk) - daptomycin 500 mg in 10 ml - daptomycin for injection is indicated for the treatment of adult patients with complicated skin and skin structure infections (csssi) caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus (including methicillin-resistant isolates), streptococcus pyogenes , streptococcus agalactiae, streptococcus dysgalactiae subsp. equisimilis , and enterococcus faecalis (vancomycin susceptible isolates only). pediatric use information is approved for merck & co., inc.'s cubicin (daptomycin for injection). however, due to merck & co., inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. daptomycin for injection is indicated for the treatment of adult patients with staphylococcus aureus bloodstream infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. pediatric use information is approved for merck & co., inc.'s cubicin (daptomyc
daptomycin- daptomycin injection, powder, lyophilized, for solution
jiangsu hengrui medicine co., ltd. - daptomycin (unii: nwq5n31vkk) (daptomycin - unii:nwq5n31vkk) - daptomycin for injection is indicated for the treatment of adult patients with complicated skin and skin structure infections (csssi) caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus (including methicillin-resistant isolates), streptococcus pyogenes, streptococcus agalactiae, streptococcus dysgalactiae subsp. equisimilis, and enterococcus faecalis (vancomycin-susceptible isolates only). pediatric use information is approved for merck & co., inc.’s cubicin (daptomycin for injection). however, due to merck & co., inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. daptomycin for injection is indicated for the treatment of adult patients with staphylococcus aureus bloodstream infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. pediatric use information is approved for merck & co., inc.’s cubicin (daptomyci
daptomycin injection, powder, lyophilized, for solution
xellia pharmaceuticals usa, llc - daptomycin (unii: nwq5n31vkk) (daptomycin - unii:nwq5n31vkk) - daptomycin for injection is indicated for the treatment of adult patients with complicated skin and skin structure infections (csssi) caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus (including methicillin-resistant isolates), streptococcus pyogenes , streptococcus agalactiae , streptococcus dysgalactiae subsp. equisimilis, and enterococcus faecalis (vancomycin-susceptible isolates only). pediatric use information is approved for merck & co., inc.’s cubicin (daptomycin for injection). however, due to merck & co., inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. daptomycin for injection is indicated for the treatment of adult patients with staphylococcus aureus bloodstream infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. pediatric use information is approved for merck & co., inc.’s cubicin (daptomy
highlights of prescribing information
hospira inc. - daptomycin (unii: nwq5n31vkk) (daptomycin - unii:nwq5n31vkk) - daptomycin for injection is indicated for the treatment of adult patients with complicated skin and skin structure infections (csssi) caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus (including methicillin-resistant isolates), streptococcus pyogenes, streptococcus agalactiae, streptococcus dysgalactiae subsp. equisimilis, and enterococcus faecalis (vancomycin-susceptible isolates only). pediatric use information is approved for merck & co., inc.'s cubicin (daptomycin for injection). however, due to merck & co., inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. daptomycin for injection is indicated for the treatment of adult patients with staphylococcus aureus bloodstream infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. pediatric use information is approved for merck & co., inc.'s cubicin (daptomyci
daptomycin for injection powder for solution
juno pharmaceuticals corp. - daptomycin - powder for solution - 500mg - daptomycin 500mg - cyclic lipopeptides